Advertisement

Topics

MVA-BN®-HER2 Vaccine in Locally Advanced & Advanced HER2+ Breast Cancer (Gene Transfer Protocol)

2014-07-24 14:00:44 | BioPortfolio

Summary

Primary Objectives:

To evaluate the safety of MVA-BN-HER2 in women with HER-2-positive breast cancer.

Secondary Objectives:

To evaluate the ability of MVA-BN-HER2 to generate humoral and cellular immune responses to HER-2, and to evaluate the duration of these responses.

Exploratory analysis comparing the ability of MVA-BN-HER2 to generate humoral and cellular immune responses to Her-2 in high risk stage III patients who have completed adjuvant chemotherapy and Trastuzumab and stage IV breast cancer patients who must receive ongoing therapy for metastatic disease.

Feasibility of completing 6 vaccines in this high risk patient population.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Breast Cancer

Intervention

MVA-BN-HER2 Vaccine

Location

Stanford University School of Medicine
Stanford
California
United States
94305

Status

Not yet recruiting

Source

Stanford University

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-24T14:00:44-0400

Clinical Trials [6845 Associated Clinical Trials listed on BioPortfolio]

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

The purpose of this study is to learn more about how to treat patients with HER-2/neu positive invasive breast cancer (IBC). HER-2/neu is a type of protein that is known to be over-express...

Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2

RATIONALE: Studying the immune response to a vaccine made from HER2/neu protein may help doctors plan better treatment for patients with breast cancer that overexpresses HER2. PURPOSE: Th...

A Study of a HER2/Neu Vaccine for Stage IIIB, IIIC and IV HER2/Neu Positive Breast Cancer Patients on Herceptin

This is a phase II, single arm (no placebo, no randomization) study in patients who: - Have HER2 overexpressing Stage IIIB, IIIC or IV breast cancer - Have been treated with Hercep...

Study of Combination Immunotherapy for the Generation of HER-2/Neu Specific Cytotoxic T Cells

This will be a single arm phase I-II single institution clinical trial in patients with HER2 overexpressing Stage IV breast and ovarian cancer who are on maintenance trastuzumab alone afte...

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

The purpose of this study is to learn more about how to treat patients with a diagnosis of diagnosis of Human Epidermal Growth Factor Receptor 2/neu (HER-2/neu) positive breast cancer in t...

PubMed Articles [15573 Associated PubMed Articles listed on BioPortfolio]

Monitoring Src status after dasatinib treatment in HER2+ breast cancer with Zr-trastuzumab PET imaging.

De novo or acquired resistance in breast cancer leads to treatment failures and disease progression. In human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer, Src, a non-recep...

LMO4 mediates trastuzumab resistance in HER2 positive breast cancer cells.

Breast cancer is the leading cause of cancer-related mortality in women worldwide. Trastuzumab (Herceptin) is an effective antibody drug for HER2 positive breast cancer; or acquired trastuzumab resis...

Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.

Resistance to HER2-targeted therapy with trastuzumab still remains a major challenge in HER2-amplified tumors. Here we investigated the potential role of MEL-18, a polycomb group gene, as a novel prog...

Patients who achieved long-term clinical complete response and subsequently terminated multidisciplinary and anti-HER2 therapy for metastatic breast cancer: A case series.

Human epidermal growth factor receptor 2 (HER2) -positive breast cancers tend to be more aggressive and more likely to recur than HER2-negative breast cancers. However, novel anti-HER2 therapies have ...

Prognostic significance of androgen receptor expression in HER2-positive and triple-negative breast cancer.

Triple-negative breast cancer (TNBC) and HER2-positive breast cancer are more aggressive than other subtypes of breast cancer. Due to the limited number of treatment alternatives and the absence o...

Medical and Biotech [MESH] Definitions

A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.

Abnormal accumulation of lymph in the arm, shoulder and breast area associated with surgical or radiation breast cancer treatments (e.g., MASTECTOMY).

Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.

A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)

A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.

More From BioPortfolio on "MVA-BN®-HER2 Vaccine in Locally Advanced & Advanced HER2+ Breast Cancer (Gene Transfer Protocol)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...


Searches Linking to this Trial